DBV Technologies S.A. (NASDAQ:DBVT)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued on Thursday. They presently have a $50.00 price target on the stock. HC Wainwright’s price objective would suggest a potential upside of 40.81% from the company’s previous close.

A number of other analysts have also recently commented on the stock. ValuEngine cut shares of DBV Technologies from a “hold” rating to a “sell” rating in a research report on Friday, June 30th. Deutsche Bank AG assumed coverage on shares of DBV Technologies in a research report on Friday, June 23rd. They issued a “buy” rating and a $46.00 price objective for the company. BidaskClub upgraded shares of DBV Technologies from a “strong sell” rating to a “sell” rating in a research report on Wednesday, June 21st. Jefferies Group LLC restated a “buy” rating and issued a $47.00 price objective on shares of DBV Technologies in a research report on Thursday, June 1st. Finally, Zacks Investment Research upgraded shares of DBV Technologies from a “sell” rating to a “hold” rating in a research report on Monday, April 24th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $47.00.

Shares of DBV Technologies (DBVT) traded up 0.59% on Thursday, hitting $35.72. The stock had a trading volume of 91,315 shares. DBV Technologies has a one year low of $31.58 and a one year high of $37.98. The company’s market capitalization is $1.64 billion. The firm has a 50 day moving average price of $34.16 and a 200 day moving average price of $34.70.

TRADEMARK VIOLATION NOTICE: “DBV Technologies’ (DBVT) “Buy” Rating Reaffirmed at HC Wainwright” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The original version of this piece can be read at https://www.americanbankingnews.com/2017/07/06/dbv-technologies-dbvt-buy-rating-reaffirmed-at-hc-wainwright.html.

Several hedge funds have recently added to or reduced their stakes in DBVT. Goldman Sachs Group Inc. boosted its stake in DBV Technologies by 3.1% in the first quarter. Goldman Sachs Group Inc. now owns 55,499 shares of the company’s stock worth $1,955,000 after buying an additional 1,647 shares in the last quarter. Point72 Asset Management L.P. purchased a new stake in DBV Technologies during the first quarter worth approximately $1,120,000. Jane Street Group LLC purchased a new stake in DBV Technologies during the first quarter worth approximately $853,000. Bank of America Corp DE boosted its stake in DBV Technologies by 86.3% in the first quarter. Bank of America Corp DE now owns 26,574 shares of the company’s stock worth $936,000 after buying an additional 12,309 shares in the last quarter. Finally, Morgan Stanley boosted its stake in DBV Technologies by 89.9% in the first quarter. Morgan Stanley now owns 249,988 shares of the company’s stock worth $8,805,000 after buying an additional 118,317 shares in the last quarter. Institutional investors and hedge funds own 48.23% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

Analyst Recommendations for DBV Technologies (NASDAQ:DBVT)

Receive News & Ratings for DBV Technologies S.A. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies S.A. and related companies with MarketBeat.com's FREE daily email newsletter.